Unveiling 4 Analyst Insights On Maravai LifeSciences
Portfolio Pulse from Benzinga Insights
Over the past three months, four analysts have shared their evaluations of Maravai LifeSciences (NASDAQ:MRVI), with all ratings being indifferent. The average 12-month price target has increased by 4.41% to $9.0. Analysts from Morgan Stanley, Goldman Sachs, and UBS have adjusted their price targets and ratings, reflecting their responses to recent developments.
August 13, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maravai LifeSciences (NASDAQ:MRVI) has received mixed evaluations from analysts over the past three months, with all ratings being indifferent. The average 12-month price target has increased by 4.41% to $9.0, indicating a slight positive sentiment. Analysts from Morgan Stanley, Goldman Sachs, and UBS have adjusted their price targets and ratings, reflecting their responses to recent developments.
The increase in the average price target by 4.41% to $9.0 suggests a slight positive sentiment among analysts. The adjustments by analysts from major firms like Morgan Stanley, Goldman Sachs, and UBS indicate a response to recent developments, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100